Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT06260514 Recruiting - Clinical trials for Advanced Solid Tumor

Study of APR-1051 in Patients With Advanced Solid Tumors

ACESOT-1051
Start date: June 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety and effectiveness of APR-1051 through the performance of a Phase 1, open-label, safety, PK, and preliminary efficacy study of oral APR-1051 in patients with advanced solid tumors.

NCT ID: NCT06259552 Recruiting - Solid Tumor Clinical Trials

A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors

SPX-303
Start date: March 20, 2024
Phase: Phase 1
Study type: Interventional

Part 1 of this study is an open-label, dose-escalation, and safety expansion study of an anti-LILRB2 / anti-PD-L1 bispecific antibody SPX- 303 in patients with solid tumors. Part 2 of this study is an indication-specific dose expansion study of SPX-303.

NCT ID: NCT06258408 Recruiting - Clinical trials for Advanced Solid Tumor

A Phase 1 Study of BB102 in Participants With Advanced Solid Tumors

Start date: December 29, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, efficacy and preliminary food effect of BB102, a highly selective and potent FGFR4 inhibitor, as monotherapy in subjects with advanced solid tumors. This study has two phase: dose escalation phase and expansion phase.

NCT ID: NCT06258330 Recruiting - Solid Tumor Clinical Trials

Study of AM003 in Patients With Locally Advanced and Metastatic Solid Tumors

Start date: June 22, 2022
Phase: Phase 1
Study type: Interventional

This is a phase 1, first-in-human study to assess the safety and tolerability of AM003 in patients with locally advanced and metastatic solid tumors

NCT ID: NCT06258304 Recruiting - Clinical trials for Advanced or Metastatic Solid Tumor Malignancies

A Dose Escalation and Expansion Study of GIGA-564 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

Start date: May 8, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of GIGA-564 and identify the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) level(s) of GIGA-564 in participants with metastatic or locally advanced solid tumor malignancies.

NCT ID: NCT06255665 Recruiting - Clinical trials for Advanced Stage Solid Tumors

A Study of JNJ-79032421 Targeting Mesothelin for Advanced Stage Solid Tumors

Start date: February 9, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine recommended phase 2 dose(s) (RP2Ds) of JNJ-79032421 and to determine the safety and tolerability of JNJ-79032421 at the RP2D(s).

NCT ID: NCT06253195 Recruiting - Breast Cancer Clinical Trials

BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Start date: April 1, 2024
Phase: Phase 1
Study type: Interventional

This is an open-label, multicenter, phase 1a/1b clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BGB-43395, a cyclin-dependent kinase 4 (CDK4) inhibitor, as monotherapy or in combination with fulvestrant, letrozole, or other combination partners in Chinese participants with hormone receptor positive (HR+) and human epidermal growth factor 2 negative (HER2-) breast cancer (BC) and other advanced or metastatic solid tumors.

NCT ID: NCT06253130 Recruiting - Clinical trials for Advanced Solid Tumor

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

Start date: December 11, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This study will evaluate the preliminary efficacy of IMP1734 in patients with recurrent advanced/metastatic breast cancer, ovarian cancer and metastatic castrate resistant prostate cancer (mCRPC) with deleterious/suspected deleterious mutations of select homologous recombination repair (HRR) genes.

NCT ID: NCT06252298 Recruiting - Clinical trials for Relapsed or Refractory Hematologic Malignancies

A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies

Start date: February 28, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of SCTC21C in patients with CD38+ hematologic malignancies

NCT ID: NCT06249256 Recruiting - Solid Tumor Clinical Trials

An Exploratory Study on the Treatment of Advanced Solid Tumors by Fast CAR T Cells

Start date: June 1, 2023
Phase: Early Phase 1
Study type: Interventional

This is a single arm, open-label, dose escalation clinical study to evaluate the safety and tolerability of fast autologous mesothelin (MSLN)-targeted chimeric antigen receptor (MSLN-CAR) T cells secreting PD-1 nanobodies in patients with solid tumors.